Aumolertinib联合或不联合化疗一线治疗EGFR突变晚期NSCLC(AENEAS2)
AENEAS2是一项在中国60家医院开展的开放标签、多中心、随机、对照3期试验,纳入624例未经治疗的EGFR敏感突变晚期NSCLC患者,随机接受Aumolertinib单药或联合铂类化疗。
要点
- 联合组3-4级中性粒细胞减少发生率为55%,单药组为1%。
- 联合组严重不良事件发生率为36%,单药组为17%。
核心结论
- Aumolertinib联合铂类化疗一线治疗EGFR敏感突变晚期NSCLC显著改善无进展生存期,但毒性增加。
研究设计与样本
- 开放标签、多中心、随机、对照3期试验,在中国60家医院开展,共随机分配624例患者。
- 患者为≥18岁、ECOG PS 0-1、未经治疗、组织学或细胞学确诊的局部晚期或转移性NSCLC,携带EGFR敏感突变(ex19del/L858R伴或不伴其他EGFR突变),允许神经稳定的脑转移。
- 按1:1随机分配至Aumolertinib单药组(110 mg口服每日一次)或联合组(Aumolertinib 110 mg每日一次+培美曲塞500 mg/m²静脉滴注+顺铂75 mg/m²或卡铂AUC 5静脉滴注,21天为一周期,共4-6周期,随后Aumolertinib+培美曲塞维持治疗)。
- 主要终点为盲法独立中心评估(BICR)的无进展生存期(RECIST 1.1版)。
主要发现
- 最常见3-4级不良事件(任一组发生率≥20%)包括中性粒细胞计数下降(联合组168/304[55%] vs 单药组4/316[1%])、白细胞计数下降(103[34%] vs 1[<1%])、血小板计数下降(62[20%] vs 2[1%])。
- 严重不良事件发生率联合组为109例(36%),单药组为53例(17%);最常见严重不良事件为血小板计数下降(22[7%] vs 0)、中性粒细胞计数下降(17[6%] vs 0)、白细胞计数下降(13[4%] vs 0)、贫血(10[3%] vs 2[1%])。
- 治疗相关死亡联合组1例(<1%,脑病),单药组2例(1%,肺栓塞和呼吸衰竭伴循环衰竭)。
关键数值与推荐
- 联合组3-4级中性粒细胞减少55%,单药组1%;严重不良事件联合组36%,单药组17%。
临床怎么用
- Aumolertinib联合铂类化疗可作为EGFR敏感突变晚期NSCLC患者的一线治疗选择,但需密切监测骨髓抑制等毒性。
- 不良反应可通过剂量调整和支持治疗进行管理,与临床实践一致。
局限性
- 总生存期数据尚未成熟,需长期随访评估。
- 开放标签设计可能引入偏倚。
- 研究仅在中国进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although third-generation epidermal growth-factor receptor (EGFR)-tyrosine-kinase inhibitors (TKIs) are standard first-line therapies for patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC), their effectiveness is often limited by the emergence of drug resistance and subsequent disease progression. Given the previously established clinical efficacy and adverse event profile of aumolertinib, we aimed to evaluate the efficacy and adverse event profile of aumolertinib in combination with platinum-based chemotherapy versus aumolertinib monotherapy as first-line treatment for patients with locally advanced or metastatic NSCLC patients with EGFR-sensitive mutations. METHODS: The open-label, multicentre, randomised, controlled, phase 3 AENEAS2 trial was done across 60 hospitals in China. Patients aged at least 18 years with Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1; treatment-naive; histologically or cytologically confirmed locally advanced or metastatic NSCLC harbouring EGFR-sensitive mutations (ex19del/L858R with or without other EGFR mutations) were eligible. Brain metastases were allowed if neurologically stable. Previous EGFR-TKI therapy was an exclusion criterion. Patients were randomly assigned (1:1) with block randomisation (block size of 6), stratified by EGFR mutation type and baseline brain metastasis, to receive aumolertinib monotherapy (110 mg orally once a day) or combination therapy (aumolertinib 110 mg orally once a day plus pemetrexed 500 mg/m2 intravenously with cisplatin [75 mg/m2] or carboplatin [area under the plasma concentration-time curve 5] intravenously on day 1 of 21-day cycles for 4-6 cycles), followed by maintenance therapy (aumolertinib 110 mg orally once a day and pemetrexed 500 mg/m2 intravenously once every 3 weeks). The primary endpoint was progression-free survival assessed by blinded independent central review (BICR; RECIST version 1.1). Efficacy was analysed in the full-analysis set, which included all randomly assigned patients, and safety was analysed in patients who received at least one dose of the actual trial treatment. The trial is registered at ClinicalTrials.gov, NCT04923906, and is ongoing, but closed to enrolment. FINDINGS: Between Aug 4, 2021, to June 18, 2024, of 1011 patients assessed for eligibility, 624 randomly assigned patients (median age 59·0 years [IQR 52·0-66·0]; 337 [54%] were female, 287 [46%] were male) were randomly assigned. 310 (50%) patients received combination therapy and 314 (50%) received monotherapy. As of the data cutoff date (June 18, 2024), the median follow-up was 23·4 months (IQR 20·5-26·5), In the full-analysis set, median BICR-assessed progression-free survival was 28·9 months (95% CI 26.3, NA) in the combination therapy versus 18·9 months (17·8-21·1) in the monotherapy (hazard ratio [HR] 0·47, 95% CI 0·37-0·60; log-rank p<0·0001). The most common grade 3-4 adverse events (occurring in at least 20% in any group) were neutrophil count decreased (168 [55%] of 304 in the combination group versus four [1%] of 316 in monotherapy group), white blood cell count decreased (103 [34%] vs one [<1%]), and platelet count decreased (62 [20%] vs two [1%]). Serious adverse events occurred in 109 (36%) patients in the combination group and 53 (17%) in the monotherapy group, the most common of which were platelet count decreased (22 [7%] vs 0), neutrophil count decreased (17 [6%] vs 0), white blood cell count decreased (13 [4%] vs 0), and anaemia (ten [3%] vs two [1%]). Treatment-related deaths occurred in one (<1%) patient in the combination group (encephalopathy) and two (1%) in the monotherapy group (pulmonary embolism and respiratory failure with circulatory collapse). INTERPRETATION: Aumolertinib in combination with chemotherapy significantly improved progression-free survival. Although this regimen was associated with increased toxicity, the side-effects were managed with dose adjustment and supportive treatment aligned with clinical practice. Long-term follow-up is required to assess overall survival. The AENEAS2 study provides evidence to guide clinical practice regarding EGFR-TKIs and their combination use in treating patients with advanced EGFR-mutated NSCLC. FUNDING: Jiangsu Hansoh Pharmaceutical Group, and the Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education & Shanghai. TRANSLATIONS: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Li Z, Hu J, Chen J, et al. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 42296979. doi:10.1016/S1470-2045(26)00090-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。